Inverse shift in serum polyunsaturated and monounsaturated fatty acids is associated with adverse dilatation of the heart

Heart

Volumn 96, Issue 8, 2010, Pages 595-598

  Rupp, H ^a   Rupp, T P ^a   Alter, P ^a   Maisch, B ^a  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

DOCOSAHEXAENOIC ACID; MONOUNSATURATED FATTY ACID; POLYUNSATURATED FATTY ACID;

ADULT; ARTICLE; ECHOCARDIOGRAPHY; FATTY ACID BLOOD LEVEL; GAS CHROMATOGRAPHY; HEART DILATATION; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE ENDDIASTOLIC PRESSURE; HEART VENTRICLE ENDDIASTOLIC PRESSURE; HUMAN; MAJOR CLINICAL STUDY; MASS SPECTROMETRY; PRIORITY JOURNAL;

ADULT; BIOLOGICAL MARKERS; CARDIOMYOPATHY, DILATED; DOCOSAHEXAENOIC ACIDS; FALSE POSITIVE REACTIONS; FATTY ACIDS, MONOUNSATURATED; FATTY ACIDS, UNSATURATED; HUMANS; MIDDLE AGED;

EID: 77950557902     PISSN: 13556037     EISSN: 1468201X     Source Type: Journal    
DOI: 10.1136/hrt.2009.176560     Document Type: Article

References (27)

1. Gissi-Hf Investigators. Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet 2008;372:1223-1230
2. Alter P, Rupp H, Rominger MB, et al. A new methodological approach to assess cardiac work by pressure-volume and stress-length relations in patients with aortic valve stenosis and dilated cardiomyopathy. Pflugers Arch 2008;455: 627-636
3. Turcani M, Rupp H. Etomoxir improves left ventricular performance of pressure-overloaded rat heart. Circulation 1997;96:3681-3686
4. Brilla CG, Funck RC, Rupp H. Lisinopril-mediated regression of myocardial fibrosis in patients with hypertensive heart disease. Circulation 2000;102:1388-1393
5. Brower GL, Chancey AL, Thanigaraj S, et al. Cause and effect relationship between myocardial mast cell number and matrix metalloproteinase activity. Am J Physiol Heart Circ Physiol 2002;283:H518-25.
6. Alter P, Rupp H, Maisch B. Activated nuclear transcription factor kappaB in patients with myocarditis and dilated cardiomyopathy - relation to inflammation and cardiac function. Biochem Biophys Res Commun 2006;339:180-187
7. Weldon SM, Mullen AC, Loscher CE, et al. Docosahexaenoic acid induces an antiinflammatory profile in lipopolysaccharide-stimulated human THP-1 macrophages more effectively than eicosapentaenoic acid. J Nutr Biochem 2007;18:250-258
8. Rupp H, Rupp TP, Alter P, et al. N-3 polyunsaturated fatty acids and statins in heart failure. Lancet 2009;373:378-379
9. Brandle M, Jacob R. Effects of a diet rich in o-3 fatty acids on left ventricular geometry and dynamics in spontaneously hypertensive rats. Eur J Appl Physiol Occup Physiol 1990;61:177-181
10. Rupp H, Rupp TP, Wagner D, et al. Microdetermination of fatty acids by gas chromatography and cardiovascular risk stratification by the "EPA+DHA level". Herz 2006;31(suppl 3):30-49.
11. Alter P, Rupp H, Rominger MB, et al. B-type natriuretic peptide and wall stress in dilated human heart. Mol Cell Biochem 2008;314:179-191
12. Alter P, Rupp H, Rominger MB, et al. Relation of B-type natriuretic peptide to left ventricular wall stress as assessed by cardiac magnetic resonance imaging in patients with dilated cardiomyopathy. Can J Physiol Pharmacol 2007;85:790-799
13. Schrecengost JE, LeGallo RD, Boyd JC, et al. Comparison of diagnostic accuracies in outpatients and hospitalized patients of D-dimer testing for the evaluation of suspected pulmonary embolism. Clin Chem 2003;49:1483-1490
14. Yasue H, Yoshimura M, Sumida H, et al. Localization and mechanism of secretion of B-type natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure. Circulation 1994;90:195-203.
15. Wang AY, Lam CW, Yu CM, et al. N-terminal pro-brain natriuretic peptide: an independent risk predictor of cardiovascular congestion, mortality, and adverse cardiovascular outcomes in chronic peritoneal dialysis patients. J Am Soc Nephrol 2007;18:321-330
16. Foo K, Cooper J, Deaner A, et al. A single serum glucose measurement predicts adverse outcomes across the whole range of acute coronary syndromes. Heart 2003;89:512-516
17. Leaf A, Albert CM, Josephson M, et al. Prevention of fatal arrhythmias in high-risk subjects by fish oil n-3 fatty acid intake. Circulation 2005;112:2762-2768
18. Billman GE, Hallaq H, Leaf A. Prevention of ischemia-induced ventricular fibrillation by omega 3 fatty acids. Proc Natl Acad Sci USA 1994;91:4427-4430
19. Albert CM, Campos H, Stampfer MJ, et al. Blood levels of long-chain n-3 fatty acids and the risk of sudden death. N Engl J Med 2002;346:1113-1118
20. Siscovick DS, Raghunathan TE, King I, et al. Dietary intake and cell membrane levels of long-chain n-3 polyunsaturated fatty acids and the risk of primary cardiac arrest. JAMA 1995;274:1363-1367
21. GISSI-Prevenzione Investigators. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI- Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico. Lancet 1999;354:447-455
22. Duda MK, O'Shea KM, Tintinu A, et al. Fish oil, but not flaxseed oil, decreases inflammation and prevents pressure overload-induced cardiac dysfunction. Cardiovasc Res 2009;81:319-327
23. Levick SP, Gardner JD, Holland M, et al. Protection from adverse myocardial remodeling secondary to chronic volume overload in mast cell deficient rats. J Mol Cell Cardiol 2008;45:56-61.
24. Forman BM, Chen J, Evans RM. Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors alpha and delta. Proc Natl Acad Sci USA 1997;94:4312-4317
25. Jump DB. The biochemistry of n-3 polyunsaturated fatty acids. J Biol Chem 2002;277:8755-8758
26. Staels B, Koenig W, Habib A, et al. Activation of human aortic smooth-muscle cells is inhibited by PPARalpha but not by PPARgamma activators. Nature 1998;393:790-793
27. Barger PM, Brandt JM, Leone TC, et al. Deactivation of peroxisome proliferator-activated receptor-alpha during cardiac hypertrophic growth. J Clin Invest 2000;105:1723-1730